

Medgen, Inc.
Quarterly Report
For the Three Months
Ended December 31, 2015

ITEM 1. EXACT NAME OF ISSUER AND ITS PREDECESSORS	2
ITEM 2. ADDRESS OF ISSUERS PRINCIPAL EXECUTIVE OFFICES	2
ITEM 3. SECURITY INFORMATION	2
ITEM 4. ISSUANCE HISTORY	3
ITEM 5. FINANCIAL STATEMENTS	5
ITEM 6. ISSUERS BUSINESS, PRODUCTS AND SERVICES	16
ITEM 7. DESCRIPTION OF THE ISSUERS FACILITIES	16
ITEM 8. OFFICERS, DIRECTORS, AND CONTROL PEOPLE	17
ITEM 9. THIRD PARTY PROVIDERS	17
ITEM 10. ISSUER CERTIFICATION	18

Item 1. The exact name of the issuer and its predecessors

Medgen, Inc.
Formerly Northstar Global Business Services, Inc.

Item 2. The address of the Issuers principal executive offices

Company Headquarters & IR Contacts
20 Peachtree Court Suite 103H
Holbrook, NY, 11741
Telephone: 877-571-4387
info@medgeninc.com

Item 3. Security Information

Trading Symbol: MDIN
CUSIP: 58436J100
Par value: \$0.001

As of 12/31/15 there are:

3,000,000,000 Common shares authorized
1,824,054,852 Common shares outstanding
5,000,000 Preferred shares authorized
3,000,000 Preferred shares outstanding

Transfer Agent is:
SIGNATURE STOCK TRANSFER, INC.
2632 Coachlight Court
Plano, Texas 75093
Telephone 972.612.4120
Facsimile 972.612.4122

- (i) Transfer agent IS registered under the Exchange Act (YES)
- (ii) There are no restrictions on the transfer of securities
- (iii) There have been NO trading day suspensions ordered by the SEC in the past 12 months.

Item 4. Issuance History

As of December 31, 2015 – For the past three (3) months, the following issuances have taken place:

Item 5. Financial Statements

**Matthew Briggs
20 Peachtree Court Suite
103H Holbrook, NY 11741
877-571-4387**

February 16, 2015
Board of Directors of Medgen, Inc.
20 Peachtree Court, Suite 103H
Holbrook, NY 11741

Per my position as CEO and Treasurer for Medgen, Inc. (the “Company”), I have prepared and compiled the accompanying balance sheet of the Company as of December 31, 2015 and the related Statements of Income and Changes in Cash Flows for the three months then ended, including the financial notes, using the generally accepted accounting principles accepted in the United States of America.

/s/ Matthew Briggs
Chief Executive Officer

Medgen, Inc.
Consolidated Balance Sheets
For the Period Ending
December 31, 2015 and December 31, 2014

	31-Dec-15 (unaudited)	31-Dec-14 (unaudited)
Assets		
Current Assets		
Cash and cash equivalents	\$44	\$9,809
Inventory	2,357	31,780
Total current assets	2,401	41,589
Intangible Assets	112,752	112,752
Goodwill	121,425	121,425
Total Assets	<u>\$236,578</u>	<u>\$275,766</u>
Liabilities and Equity(Deficit)		
Current Liabilities		
Accrued expenses	-\$12,349	-\$5,918
Derivative liability	-69,662	-82,406
Notes payable	-264,720	-22,915
Total Current Liabilities	-346,731	-111,239
Long-Term Liabilities	-	-
Total Liabilities	-346,731	-111,239
Commitments and Contingencies		
Medgen Inc."MDIN" Stockholders' Equity		
Preferred stock, par value \$0.0001; 5,000,000 shares authorized; 3,000,000 issued and outstanding at 12/31/15 and 2,000,000 issued and outstanding at 12/31/14	300	200
Common stock, par value \$0.001; \$3,000,000,000 shares authorized; 1,824,054,852 shares issued and outstanding at 12/31/15 and 1,497,814,753 shares issued and outstanding 12/31/14	1,824,054	1,497,815
Treasury Stock	-	-
Additional contributed capital in excess of par	31,723,848	31,723,848
Accumulated deficit	-33,057,336	-33,057,336
Total Equity(Deficit)	-110,153	15,789
Total Liabilities and Equity(Deficit)	<u>\$275,766</u>	<u>\$275,766</u>

See accompanying notes to financial statements.

"See accompanying notes to financial statements."

Medgen, Inc.
Consolidated Statements of Operations
For the Period Ending
December 31, 2015 and December 31, 2014

	For the Three Months Ended	
	31-Dec-15 (unaudited)	31-Dec-14 (unaudited)
Sales	<u>\$8,205</u>	<u>\$6,569</u>
Cost of Sales	-1,111	4,402
Gross Profit	<u>\$7,093</u>	<u>\$2,167</u>
Total operating expenses	<u>-\$9,706</u>	<u>\$29,261</u>
Net loss from operations before other income(expense)	-2,613	-27,094
Other income(expense)		
Interest Expense	-75,170	-50,223
Derivative gain(loss)	20,906	-634
Net income(loss) before provision for income taxes	<u>-\$56,877</u>	<u>-\$77,951</u>
Provision for income taxes	-	-
Net loss	<u>-\$56,877</u>	<u>-\$77,951</u>
Net loss per share: Basic and diluted	<u>-</u>	<u>-</u>
Weighted average number of shares outstanding: Basic and diluted	<u>1,824,054,852</u>	<u>1,497,814,753</u>

See accompanying notes to
financial statements.

"See accompanying notes to financial statements."

Medgen, Inc.
Consolidated Statements of Cash Flows
For the Period Ending
December 31, 2015 and December 31, 2014

	For the Three Months Ended	
	31-Dec-15	31-Dec-14
	(unaudited)	(unaudited)
Cash flows from operating activities		
Net loss for the period	-\$56,877	-\$77,951
Adjustments to reconcile net loss to net cash (used in) operating activities:		
Stock issued as compensation for services	-	-
Loss on derivative liability	13,574	46,022
Amortization of debt discount	43,535	11,250
Changes in assets and liabilities:		
(Increase) decrease in inventory	\$1,224	\$434
Increase (decrease) in accrued expenses	-	3,085
Net cash used in operating activities	-\$9,706	-\$17,160
Cash flows from investing activities		
None	-	-
Net cash flows (used) by investing activities	-	-
Cash flows from financing activities		
Proceeds from sale of common stock	-	-
Proceeds from notes payable	2,000	25,000
Net cash flows provided(used) by financing activities	2,000	25,000
Net increase(decrease) in cash	-613	7,840
Cash, beginning of period	657	1,969
Cash, end of period	\$44	\$9,809
Supplemental disclosure of cash flow information:		
Interest paid	\$-	\$-
Income taxes paid	\$-	\$-
Supplemental disclosure of non cash activities:		
None	\$-	\$-

See accompanying notes to financial statements.

"See accompanying notes to financial statements."

MEDGEN, INC.
Financial Notes for Period Ended
December 31, 2015 and December 31, 2014

NOTE 1- ORGANIZATION AND BASIS OF PRESENTATION

Medgen, Inc. formerly Northstar Global Business Services, Inc. (the "Company" or "Medgen"), Formerly Med Gen, Inc. (the "Company") was established under the laws of the State of Nevada in October 1996. The Company's common stock traded on the OTC Bulletin Board under the symbol "MDIN.OB".

The Company was established to manufacture, sell and license healthcare products, specifically to the market for alternative therapies (health self-care). One out of every three households practice some form of alternative therapies. Industry observers estimate this market's size at \$100 billion a year, which includes the diet category, a level of consumer expenditure almost triple the level of expenditure in 1990.

The two most prominent factors contributing to this robust growth were (i) increased levels of education among consumers; and, ii) changing patterns of primary care (both in cost and in delivery).

In 2005, because of a need to fund its new Direct to Consumer marketing plan (DTC) which, essentially shut off revenue created from the retail sales of its products. This conversion was estimated to cost over \$2M. To help finance this conversion and future growth, management started a Financial Consulting service, offering their years of experience, insight and practical know-how to officers of other Public Companies.

The idea caught on with the company's lenders and they recommended potential clients. These, along with other contacts, were the building blocks that produced earnings during this reporting period for the company. Earnings exceeded \$1.3 million and provided the majority of capital necessary to continue the marketing conversion as well as the completion of the company's newest product FabULustTM. The greatest assets of the company at this time were found in its stable of uniquely designed products. These products, which have been carefully researched, addressed markets that exceeded \$100 Billion and will eventually grow Med Gen.

On April 1, 2009, shareholders approved a reverse split of the outstanding shares of common stock at the rate of one-for-two thousand (1:2000) reducing the outstanding shares to approximately 1,026,961.

On July 28, 2009 Majority shareholders Mr. Paul Mitchell and Mr. Paul Kravitz resigned their Officer and Board positions, and on July 30, 2009, Lorin R. Streim, Esq. was appointed as a board member and as the transitional Chief Executive Officer of Med Gen Inc. At this time, a group of individuals associated with NorthStar Business & Property Brokers, Inc., a privately held company incorporated in the state of Delaware, indicated interest in a stock exchange with Med Gen Inc. and re-directing the business activities of Med Gen Inc. NorthStar Business & Property Brokers, Inc. ("NorthStar") was primarily engaged in the business of business brokerage and as such, Ms. Streim appointed Mr. Raymond Barton, the Chief Executive Officer of NorthStar, as the Director of the company on February 9, 2010. Several individuals associated with NorthStar were subsequently elected to the Board and as various officers of the company by Unanimous Written Consent of the Board of Directors dated February 19, 2010.

On February 10, 2010 Company entered into a loan agreement with NIR Group LLC to receive funding of up to \$3,000,000 through a series of convertible debentures carrying 8 % interest with a conversion price equal to the average of the three (3) lowest intra-day prices for the common stock in the prior twenty (20) trading days. \$116,000 of this note was received initially and proceeds from this loan were devoted to moving the corporate offices from Florida to Holbrook, New York, purchasing office equipment, furniture and supplies, payment of outstanding corporate debts to various vendors and generally revitalizing and re-directing the business activities of the Company that had been minimal since 2008 and the departure of former management in July, 2009.

On March 30, 2010 The Company entered into a second loan agreement with Raymond H. Barton, the company CEO at the time for \$78,000, which was used as investment into the infrastructure of the Company. Company management also expects at this time to devote a portion of these proceeds to the marketing & advertising campaigns of its wholly owned subsidiary NorthStar Business & Property Brokers, Inc., a private company engaged primarily in business brokering.

On July 13, 2010 the Board of Directors and the majority shareholders of the Company approved a 1:30 reverse stock split for its common stock. The Action was subsequently approved by FINRA to become Effective August 4, 2010. The symbol would remain "MDIN", and all fractional shares were rounded up at that time. The Company had 11,370,749,992 shares of common stock outstanding and post split reduced that number to 379,024,992 shares. The Company also changed its name to Medgen, Inc. with a Certificate of Amendment filed with the Nevada Secretary of State on July 14, 2010. This change in name was approved by resolution of the Board of Directors and the majority shareholders of the Company on July 13, 2010 as well, and was included

in the OTC Equity Issuer Notification package submitted to FINRA on July 22, 2010 notifying FINRA of both the name change and intended reverse stock split.

Over the period from July 2010 to March 2011, the company set up offices in Holbrook, NY. Although several websites were set up and national marketing campaigns ran, the cost of the set up and marketing offset any income leaving the company with zero (0) net income and insufficient operating expenses. This was due mostly to the steep decline in the US economy and a major change in the buying of small to midsize businesses.

On Nov 15, 2010 all board members and company executives except the CEO, President and chairman, Raymond Barton had resigned from the company. The changes were not made with the Nevada Secretary of State nor OTC Markets due to lack of funds to pay the appropriate filings fees.

On March 25, 2011, Raymond Barton resigned from the company and Nicholas Chieco was appointed to take his place in order to manage the company and seek funding along with suitable business venture in order to rebuild the company. 200 Million shares were issued to Mr. Chieco in exchange for his services bringing the total outstanding to 635,652 at that time.

On December 17, 2012 the company cancelled 133,333,333 shares previously issued to principals of the company who resigned and forfeited their ownership. This brought the outstanding down to 502,319,415 shares.

On December 31st of 2012 it was found that during the transfer of company account to the current transfer agent, several certificates were re-issued as free trading under rule 144 due to waiting period expiration by the previous transfer agent, Continental Transfer and & Trust co. At that time Continental claims to have been under the impression they were still acting transfer agent due to an outstanding balance owed by the company. These shares were listed as restricted by the current transfer agent since they had no knowledge of this. The shares were remnants of certificates issued before 2010 and there exists no legal bounds to refuse re-issuance. As a result the public float was adjusted retroactively to 238,986,082. No additional shares have been issued this quarter.

On February 27th, 2013 through March 31st, 2013, the company purchased shares in a pre announced buyback and share cancellation to decrease the number of outstanding shares. As of March 31st 2013, Approximately thirty three million shares of those bought back have cleared and are in company treasury. Another sixty six million are in the process of being re-issued to the treasury. It is the company's goal that a yet undetermined portion of the treasury shares will be canceled and removed from the outstanding shares sometime in near future.

In May 2013 the company retired 71,000,000 shares of common stock that the company had previously acquired through share returns.

On May 20, 2013 the Company terminated a letter of intent to acquire a patent license from Celprogen Inc. for an unlimited license to use their patent for a lactose intolerance cure and the only term is that the company pay a 2% royalty on the net profit generated annually in exchange for 400,000,000 common shares.

In September 2013 the Company retired 30,033,333 shares of common stock previously issued to prior board members.

In 2015, the company changed its name back to its original name, Medgen, Inc., retaining the trading symbol, MDIN.

NOTE 2- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation:

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Northstar Business and Property Brokers, Inc.. All significant inter-company accounts and transactions have been eliminated in consolidation.

Use of Estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents:

For financial statement presentation purposes, short-term, highly liquid investments with original maturities of three months or less are considered to be cash equivalents. The Company maintains its cash accounts at several financial institutions, which at times may exceed the insurable FDIC limit, but management believes that there is little risk of loss.

Fair Value of Financial Instruments:

In September 2006, the Financial Accounting Standards Board (FASB) introduced a framework for measuring fair value and expanded required disclosure about fair value measurements of assets and liabilities. The Company adopted the standard for those financial assets and liabilities as of the beginning of the 2008 fiscal year and the impact of adoption was not significant. FASB Accounting Standards Codification (ASC) 820 “*Fair Value Measurements and Disclosures*” (ASC 820) defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

- Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
- Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability; either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g. interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3—Inputs that are both significant to the fair value measurement and unobservable.

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include investments in available-for-sale securities and accounts payable and accrued expenses. The Company has also applied ASC 820 for all non-financial assets and liabilities measured at fair value on a non-recurring basis. The adoption of ASC 820 for non-financial assets and liabilities did not have a significant impact on the Company’s financial statements.

Comprehensive Income:

ASC Topic 220 (SFAS No. 130) establishes standards for reporting comprehensive income and its components. Comprehensive income is defined as the change in equity during a period from transactions and other events from non-owner sources. Per the consolidated financial statements, the Company has purchased available-for-sale securities that are subject to this reporting.

Other-Than-Temporary Impairment:

All of our non-marketable and other investments are subject to a periodic impairment review. Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. When events or changes in circumstances indicate that long-lived assets other than goodwill may be impaired, an evaluation is performed to determine if a write-down to fair value is required. When an asset is classified as held for sale, the asset’s book value is evaluated and adjusted to the lower of its carrying amount or fair value less cost to sell. In addition, depreciation and amortization ceases while it is classified as held for sale.

The indicators that we use to identify those events and circumstances include:

- The investee’s revenue and earnings trends relative to predefined milestones and overall business prospects;
- The general market conditions in the investee’s industry or geographic area, including regulatory or economic changes;
- Factors related to the investee’s ability to remain in business, such as the investee’s liquidity, debt ratios, and the rate at which the investee is using its cash; and
- The investee’s receipt of additional funding at a lower valuation. If an investee obtains additional funding at a valuation lower than our carrying amount or a new round of equity funding is required for the investee to remain in business, and the new round of equity does not appear imminent, it is presumed that the investment is other than temporarily impaired, unless specific facts and circumstances indicate otherwise.

Revenue and Cost Recognition:

The Company applies paragraph 605-10-S99-1 of the FASB Accounting Standards Codification for revenue recognition. The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the sales price is fixed or determinable, and (iii) collectability is reasonably assured. More than ninety percent of our revenue comes from distribution agreements where all or some of the revenue earned may be adjusted or refunded based on product sales and for accounting purposes should be considered deferred revenue.

Allowance for Doubtful Accounts:

The Company establishes an allowance for doubtful accounts through a review of several factors, including historical collection experience, current aging status of the customer accounts and the financial condition of the customers.

Fixed Assets: Fixed assets are reported at cost less accumulated depreciation, which is generally provided on the straight-line method over the estimated useful lives of the assets. Upon sale or retirement of an asset, the related costs and accumulated depreciation are removed from the accounts and any gain or loss is recognized.

Financing Fees: Financing fees are being amortized over the life of the related liability on the straight-line method which is not materially different than using the effective interest method.

Goodwill and Intangible Assets Arising from Acquisitions:

The reported amounts of goodwill for each business-reporting unit are reviewed for impairment on an annual basis and more frequently when negative conditions such as significant current or projected operating losses exist. The annual impairment test for goodwill is a two-step process and involves comparing the estimated fair value of each business-reporting unit to the business-reporting unit's carrying value, including goodwill. If the fair value of a business-reporting unit exceeds its carrying amount, goodwill of the business reporting unit is not considered impaired, and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test would be performed to measure the amount of impairment loss to be recorded, if any. The Company's annual impairment tests as of September 30, 2009 resulted in recording an impairment of all of its goodwill and intangible assets and fixed assets acquired prior to 09/30/10 and no impairment to its current years acquisition Northstar Business and Property Brokers, Inc.

Evaluating Impairment of Long-lived Assets:

When events or changes in circumstances indicate that long-lived assets other than goodwill may be impaired, an evaluation is performed. For an asset classified as held for use, the estimated future undiscounted cash flows associated with the asset are compared to the asset's carrying amount to determine if a write-down to fair value is required. When an asset is classified as held for sale, the asset's book value is evaluated and adjusted to the lower of its carrying amount or fair value less cost to sell. In addition, depreciation and amortization ceases while it is classified as held for sale.

Net Loss Per Share:

Net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (EPS) include additional dilution from common stock equivalents, such as stock issuable pursuant to the exercise of stock options and warrants. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive. The following is a reconciliation of the computation for basic and diluted EPS for the years ended December 31, 2015 and 2014:

	31-Dec-15	31-Dec-14
(A) Net Income(Loss)	\$ -56,877	\$ 9,118
(B) Weighted Average Common Shares Outstanding - Basic	1,824,054,852	701,286,082
Basic income (loss) per share: (A)÷(B)	\$ (0.000031)	\$ (0.0008)
Equivalents		

Stock Options	0	0
Warrants	0	0
Convertible notes	2,647,200,000	1,542,750,000
Weighted Average Common Shares Outstanding - Diluted	4,471,254,852	701,286,082
Basic and diluted income (loss) per share:	\$ (0.00001)	\$ (0.0000)

Income Taxes:

The Company recognizes the amount of taxes payable or refundable for the year. In addition, deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been recognized in the financial statements or tax returns. A valuation allowance is provided for deferred tax assets if it is more likely than not that these items will not be realized.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. The Company is in the process of bringing its tax filings current.

Recently Issued Accounting Pronouncements:

In May 2009, the FASB issued SFAS No. 165, *Subsequent Events* (“SFAS 165” or ASC 855). SFAS 165 (ASC 855) establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. SFAS 165 (ASC 855) sets forth (1) The period after the balance sheet date during which management of a reporting entity should evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements, (2) The circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements and (3) The disclosures that an entity should make about events or transactions that occurred after the balance sheet date. SFAS 165 (ASC 855) was effective for interim or annual financial periods ending after June 15, 2009.

In June 2009, the FASB issued SFAS No. 168, *The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles—a replacement of FASB Statement No. 162* (“SFAS 168” or ASC 105-10). The FASB Accounting Standards Codification (“Codification”) will be the single source of authoritative Non-governmental U.S. generally accepted accounting principles. Rules and interpretive releases of the SEC under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. SFAS 168 (ASC 105-10) was effective for interim and annual periods ending after September 15, 2009. All existing accounting standards are superseded as described in SFAS 168. All other accounting literature not included in the Codification is non-authoritative. Existing GAAP was not intended to be changed as a result of the Codification, and accordingly the change did not impact our financial statements. The ASC does change the way the guidance is organized and presented.

In October 2009, the FASB issued Accounting Standard Update (“ASU”) No. 2009-13, *Multiple-Deliverable Revenue Arrangements* (“ASU 2009-13). This standard updates FASB ASC 605, *Revenue Recognition* (“ASC 605”). The amendments to ASC 605 requires entities to allocate revenue in an arrangement using estimated selling prices of the delivered goods and services based on a selling price hierarchy. These amendments to ASC 605 should be applied on a prospective basis for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010, with early adoption permitted. The Company adopted these amendments on January 1, 2010. Management does not believe that the adoption of this standard will have any impact on the Company’s financial statements.

In January 2010, the FASB issued ASU No. 2010-06, *Fair Value Measurements and Disclosures* (“ASU 2010-06”). This standard updates FASB ASC 820, *Fair Value Measurements* (“ASC 820”). ASU 2010-06 requires additional disclosures about fair value measurements including transfers in and out of Levels 1 and 2 and separate disclosures about purchases, sales, issuances, and settlements relating to Level 3 measurements. It also clarifies existing fair value disclosures about the level of desegregations and about inputs and valuation techniques used to measure fair value. The standard is effective for interim and annual reporting periods beginning after December 15, 2009 except for the disclosures about purchases, sales, issuances and settlements which is effective for

fiscal years beginning after December 15, 2010 and for interim periods within those fiscal years. The Company adopted ASU 2010-06 on January 1, 2010, which had no material impact on the financial statements. Other recent accounting pronouncements issued by the FASB (including its EITF), the AICPA, and the SEC did not or are not believed by management to have a material impact on the Company's present or future financial statements.

NOTE 3- ACCOUNTS RECEIVABLE

The company has shown \$0 in receivables At December 31, 2015. This is an amount currently outstanding and invoiced as of the end of this period, the majority of which is pertaining to retail distribution agreement(s) calling for a defined number of units of product. In most cases where retail sales are concerned, standard agreements allow for units not sold within the period to be returned or credited to the purchaser thereby making this revenue technically deferred revenue since it cannot be completely considered total until the end of the specific period which varies.

NOTE 4 ACQUISITIONS AND INTANGIBLES

On March 30, 2010, Medgen, Inc. purchased 100% of the outstanding stock of Northstar Business and Property Brokers, Inc. in exchange for 3,000,000,000 of fully vested shares of restricted common stock, which were valued at \$.0001 per share or \$300,000, which was attributed to goodwill. This acquisition was deemed not material to the financial position of the Company. The Company has since suspended Northstar Business and Property Brokers operations and all of the assets have been recorded at zero value as of September 30, 2011. The acquisition was also accounted for as business purchases and recorded at the estimated fair values of the net tangible and identifiable Intangible assets acquired. Additionally, the excess of the purchase price over the assets acquired was recorded as goodwill.

Intangible assets consist of the following:

	<u>31-Dec-15</u>	<u>31-Dec-14</u>
Licenses and Trademarks	\$ 1,406,150	\$ 1,406,150
Non-compete agreement	180,070	180,070
Customer list	334,866	334,866
	<u>1,921,086</u>	<u>1,921,086</u>
Less: Accumulated amortization	415,328	415,328
Impairment	<u>1,393,006</u>	<u>1,393,006</u>
Intangible assets, net	<u><u>112,752</u></u>	<u><u>112,752</u></u>
Goodwill	440,600	440,600
Less: Impairment	<u>319,175</u>	<u>319,175</u>
Goodwill, net	<u><u>\$ 121,425</u></u>	<u><u>\$ 121,425</u></u>

NOTE 5- CONVERTIBLE NOTES PAYABLE

To the best knowledge of management the amount of convertible debentures that were issued previously, were converted into common shares, and no further convertible debentures exists in reference to these past notes except loans payable to shareholder's as outlined separately below in note 8.

NOTE 6- LONG-TERM LIABILITIES

There are currently no long-term liabilities to report.

NOTE 8- LOAN PAYABLE TO SHAREHOLDERS

As of December 31, 2015 \$264,614 of “Loans payable to related party” represents a series of loans from former officer, Ray Barton, Eastlight Enterprises, Global idol Capital, Inc., and Peachtree Capital, and has been used for working capital and inventory in past years. The loans are non-interest bearing, and were originally repayable by cash, or under certain circumstances by conversion into common stock at a price equal to approximately fifty percent (50%) of the current market price of the company’s common stock or various fixed market prices.

NOTE 9 – DERIVATIVE LIABILITY

The Company accounts for derivative financial instruments in accordance with ASC 815, which requires that all derivative financial instruments be recorded in the balance sheets either as assets or liabilities at fair value.

The Company’s derivative liability is an embedded derivative associated with one of the Company’s convertible promissory notes. The convertible promissory note was issued on July 14, 2014, (the "Note"), is a hybrid instruments, which contain an embedded derivative feature, which would individually warrant separate accounting as a derivative instrument under Paragraph 815-10-05-4. The embedded derivative feature includes the conversion feature to the Note. Pursuant to Paragraph 815-10-05-4, the value of the embedded derivative liability have been bifurcated from the debt host contract and recorded as a derivative liability resulting in a reduction of the initial carrying amount (as unamortized discount) of the notes, which are amortized as debt discount to be presented in other (income) expenses in the statements of operations using the effective interest method over the life of the notes.

The embedded derivative within the note have been valued using the Black Scholes approach, recorded at fair value at the date of issuance; and marked-to-market at each reporting period end date with changes in fair value recorded in the Company’s statements of operations as “change in the fair value of derivative instrument”.

As of December 31, 2015, the estimated fair value of derivative liability was determined to be \$73,328, respectively. On July 14, 2014, a derivative liability was recognized with a debt discount of \$20,000 and an expense on derivative liabilities of \$18,011. On October 8, 2014 a derivative liability was recognized with a debt discount of \$25,000 and an expense on derivative liabilities of \$45,455. In the first quarter of 2015 a derivative liability was recognized with a debt discount of \$2,700 and an expense on derivative liabilities of \$5,130. During the period ended June 30, 2015, the change in the fair value of derivative liabilities for the nine months ended June 30, 2015 was \$14,208 resulting in an aggregate gain on derivative liabilities.

Summary of Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheets:

	Carrying Value	Fair Value Measurement Using			Total
		Level 1	Level 2	Level 3	
Derivative liabilities on conversion feature	69,662	-	-	69,662	69,662
Total derivative liabilities	\$ 69,662	\$ -	\$ -	\$ 69,662	\$ 69,662

Summary of the Changes in Fair Value of Level 3 Financial Liabilities

The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended December 31, 2014:

	Derivative Liability \$
Fair value, December 31, 2014	18,011
Additions	69,525
Decrease in fair value	(17,874)
Transfers in and/or out of Level 3	-
	\$
Fair value, December 31, 2015	69,662

NOTE 10- GOING CONCERN

The Company has several distribution agreements in place laying out guidelines for the sale and delivery of its products. Most of these agreements have clauses outlining the return, refund, or credit of funds and products, if sales do not meet specific expectations. All potential revenue under these agreements must therefore be considered “potential revenue” and not earned by the company until all criteria for revenue recognition is met. Therefore in the event that demand should significantly drop, or changes within the industry should cause the products to become unsalable, some or all of the potential revenue under these agreements may not become actual revenue creating a serious cash delinquency and a serious concern as to continued operations of the company.

Furthermore since most bulk product purchases take place using a net 90 day payment model, the company is consistently paying for the manufacture of product up to 90 days before payment is received running the risk of a shortfall in cash and possible inability to produce products ordered under distribution agreements. Management believes that the Company’s capital requirements will depend on many factors including new sales initiatives, new product manufacturing, distribution expansion and the success of its products in retail as well as direct sales. The Company’s success will also depend on product rollout times, which can be lengthy in brick and mortar retail. Management also believes the Company needs to raise additional capital based on current distribution contracts for inventory manufacturing purposes. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

NOTE 11- COMMITMENTS AND CONTINGENCIES

Commitments:

The Company has currently a one-year commitment under its lease of office space located at 20 Peachtree Court, Holbrook, NY 11741 for a total of \$300 per month. This location acts as the company’s headquarters. Any other commitments leases or rentals are cancellable at any time and pose no risk of default.

NOTE 12 - DISCONTINUED OPERATIONS

During the fourth quarter of fiscal year ended September 30, 2011, the company was forced to shut down its Business Brokering locations located throughout New York due to depressed economic conditions and decreased cash flow from the lower overall activity forcing the Company to being unable to cover its fixed operating cost. The net expense of this process was recorded as discontinued operations during that fiscal year. Additionally core assets of these locations recorded in these statements as Fixed assets, Intangible assets, and Goodwill have all been deemed as impaired and the value of these assets have been written down to zero as of September 30, 2011. The Company does not expect these assets valuations to change. The current operating activity represents that of the existing business that was idle throughout the period of growth of the subsidiary, Northstar Business and Property Brokers, and is now operating once again.

NOTE 13- INCOME TAXES

As of December 31, 2015 the Company had approximately \$1,891,586 in net operating losses to carry forwards for federal income tax purposes, which expire between 2011 and 2029 held between its various subsidiaries. We are currently using a 35% effective tax rate for our projected available net operating loss carry forward. However, as a result of potential stock offerings and stock issuance in connection with potential acquisitions, as well as the possibility of the Company not realizing it’s business plan objectives and having future taxable income to offset, the Company’s use of these NOLs may be limited under the provisions of Section 382 of the Internal Revenue Code of 1986, as amended. The Company is in the process of evaluating the implications of Section 382 on its ability to utilize some or all of its NOLs.

**End Financial Notes for Period Ended
December 31, 2015 & December 31, 2014**

Item 6. Description of the Issuer's Business, Products, and Services

- A. Medgen, Inc. Inc. manufactures and distributes alternative healthcare products in the alternative, self-help health and wellness industry and distributed via direct online sales as well as far-reaching retail distribution through its many partners' including both large retail chains like Target, Wal-Mart, Walgreens, CVS Caremark, and Rite-Aid, as well as individual stores and "Mom and Pop" shops across the country.
- B. Medgen, Inc., formerly Northstar Global Business Services, Inc. (the "Company" or "Medgen") was established under the laws of the State of Nevada in October 1996, but effected a change in domicile in 2015 to Wyoming.
- C. The Issuer's primary SIC code is 8082, Home health care services.
- D. The Issuer's Fiscal year end is September 30th.
- E. The issuers principal products are:

SNORenz® is a lubricating throat spray that is an effective, non-intrusive snoring remedy that works to offer pleasant relief from the disruptive noise made by snoring. An all-natural and effective combination of E Vitamins, B6 and Natural Oils is administered direct to the throat's soft palate (uvula), gently lubricating the area prone to vibration and reducing snoring noise. As a spray alternative SNORenz® removes the need to swallow and digest large, uncomfortable pills that can have a delayed and variable effect. Its fine mist moistens the soft palate instantly, providing lubrication, whilst its natural peppermint extract aids fresh breath and combats the morning after sluggishness of most snoring medication.

SNORenz Night Time © is a lubricating throat spray and all natural supplement sleep aid that is an effective, nonintrusivesnoring remedy and sleep inducer that works to offer pleasant relief from the disruptive noise made by snoring. An all-natural and effective combination of vitamins and supplements including Melatonin, Chamomile extract, Kava Kava and several others, blended in quantities medically proven to bring on a rich deep sleep without the sluggishness and tiredness that accompanies most sleep aids.

Health Enrich for Pets© is the first MedGen product for pets. Primarily for Dogs and Cats, HE for Pets is an incredible anti-inflammatory and a catalyst that causes the body to be flooded with adult stem cells. This rebuilds, and heals and helps aging pets to get back on their feet again! The feed back for HE for Pets has been amazing and claims are that aging pets barely able to walk have began running around the yard after just a few days of using HE for pets. Made from extract of aquatic algae, it's all natural and healthy, bringing all kinds of health benefits.

Stem-Intense© is an all natural supplement made from a unique extract found in certain types of aquatic algae along with a proprietary mix of vitamins, amino acids and proteins. After ingesting just a few milligrams of Stem-Intense©, your body gets flooded with approximately 400 times the normal amount of adult stem cells, cells that can become just about any cell in your body. When you work out, your body repairs the damaged muscle, and usually has to build them from scratch out of amino acids and other building blocks. Stem-Intense© speeds up the process by allowing the free-flowing stem cells to immediately begin becoming new muscle cells and adding to your muscle bulk. Clinical trials done by an independent 3rd party have proven that the active ingredient in Stem-intense© can build damaged tissue like muscle up to 300 times faster than the body normally can. Although a new product, Stem-Intense has lots of interest both from retail and from consumers alike.

Wide Awake™ is the newest product in the Medgen family. The unique product merges the company's successful oral spray delivery method with a concentrated, caffeinated stimulant to create the world's best oral energy spray. Natural Peppermint oil gives it a strong mint taste for fresh breath that accompanies the rush of energy people associate with energy drinks or shots but requires just a few sprays in the mouth to achieve its goal instead of digesting an entire drink.

Item 7. Description of the Issuers facilities

Medgen, Inc.'s only facility at the moment is 500 sqft of leased office space. Since most of the company operations are outsourced, there is no need for large facilities at this time. The terms of the lease are three hundred dollars (\$ 300.00) per month, for one year starting On October 1 2015, and the company can cancel at anytime after that period. The facilities are located at: 20 Peachtree Court Suite 103H Holbrook, NY 11741

Item 8. Officers Directors and Control Persons

- A. As of the date of this information statement, Matthew Briggs is the only individual who is an officer, director, or control position. He holds the following positions:

Matthew Briggs
CEO, Secretary, Treasurer, Chairman & Director
20 Peachtree Court Suite 103H
Holbrook, NY 11741

- B. Mr. Briggs has no disciplinary history whatsoever, and has never had a criminal conviction, entry of a judgment or decree by a court of any jurisdiction that limited his involvement with any type of business, securities, commodities, or banking activities. Furthermore he has never had a finding or judgment against him nor any order by self-regulatory organizations of any kind.
- C. As of the date of this information statement the only individual or entity owning more than 10% of the company's common or preferred securities is as follows:

Nicholas Chieco
15 Bear Street
Selden, NY 11784
2,000,000 Shares of Preferred Series A

Item 9. Third Party Providers

The following provide services to the Issuer:

SIGNATURE STOCK TRANSFER, INC.
2632 Coachlight Court
Plano, Texas 75093
Telephone 972.612.4120
Facsimile 972.612.4122

(The rest of this page is left intentionally blank)

Item 10. Issuer Certification

I, Matthew Briggs, certify that:

I have reviewed this quarterly statement of Medgen, Inc.; and

Based on my knowledge, to the best of my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

Based on my knowledge, to the best of my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: February 16, 2015

/s/ Matthew Briggs

Chief Executive Officer, Secretary & Treasurer
